Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04654052 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

VerifyNow to Optimise Platelet Inhibition in Coronary Acute Syndrome

Study acronym: VERONICA
StatusCompleted
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial completed Primary completion date changed from estimate of Dec 3, 2026 to Jul 29, 2026 · Enrollment target: estimated 634 to confirmed 637 · Study completion date changed from estimate of Dec 4, 2026 to Aug 5, 2026 · 2 more Show 5 more changesShow less
    • Primary completion date changed from estimate of Dec 3, 2026 to Jul 29, 2026
    • Enrollment target: estimated 634 to confirmed 637
    • Study completion date changed from estimate of Dec 4, 2026 to Aug 5, 2026
    • Eligibility criteria expanded, about 11 words
    • Publications: details revised at 8 of 8 entries
  2. Primary completion date: Dec 1, 2025 to Dec 3, 2026 Completion date: Dec 1, 2025 to Dec 4, 2026v20 Show 1 more changeShow less
    • Completion date: Dec 1, 2025 to Dec 4, 2026
  3. Primary and study completion dates: Jun 1, 2023 to Dec 1, 2025 Trial status: Recruiting to Active, Not Recruiting · Site details revised at 19 of 19 sitesv19 Show 2 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 19 of 19 sites
  4. Study sites: 18 to 19v18
  5. Study sites: 17 to 18v17
Show 15 earlier versionsHide 15 earlier versions
  1. Study sites: 16 to 17v16
  2. Study sites: 15 to 16v15
  3. Study sites: 13 to 15v14
  4. Study sites: 12 to 13v13
  5. Study sites: 11 to 12v12
  6. Primary completion date: Jun 1, 2022 to Jun 1, 2023 Study sites: 10 to 11v11 Show 1 more changeShow less
    • Study sites: 10 to 11
  7. Study sites: 8 to 10v10
  8. Study sites: 7 to 8v9
  9. Study sites: 6 to 7v8
  10. Study sites: 5 to 6v7
  11. Study sites: 3 to 5v6
  12. Study sites: 2 to 3v5
  13. Site details revised at 1 of 2 sitesv4
  14. Start date: Jun 24, 2021 to Jul 2, 2021v3
  15. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of May 1, 2021 to Jun 24, 2021 · Site details revised at 2 of 2 sitesv2 Show 2 more changesShow less
    • Start date changed from estimate of May 1, 2021 to Jun 24, 2021
    • Site details revised at 2 of 2 sites
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The objective of the study is to establish a de-scaling strategy of P2Y12 inhibitors (P2Y12 i) with a decrease in hemorrhagic events without increasing ischemic complications based on a Platelet Function Test (PFT).
Trial Details
NCT Number NCT04654052
Lead Sponsor Fundación EPIC
Conditions Acute Coronary Syndrome, Acute Myocardial Infarction, Coronary Artery Disease, Percutaneous Coronary Intervention
Enrollment 637 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov